Neogen Corporation

NEOG • Medical - Devices

$11.72

— 0.00 (0.00%)

Precio actual

ResultadosÚltimo reporte: 31 ago 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$2.56B

Crecimiento

7.8%

Flujo de caja

2/5

Tendencia

Volatile

Evidencia

Flujo de caja libre positivo · 0.68Nivel de deuda manejable · 0Liquidez saludable · 3.82Rentabilidad débil

Datos financieros hasta: 31 ago 2026, 12:00 a.m. UTCÚltima actualización de earnings: 31 ago 2026, 12:00 a.m. UTCÚltima actualización del perfil: 8 oct 2026, 12:05 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$11.72

Change0.00%

Shares Out218.10M

Market Cap$2.56B

Enterprise Value$2.38B

52W Range5.37 - 14.26

Beta1.79

P/E-45.54

P/S2.89

P/B1.23

P/FCF-1,182.85

EV/Sales2.70

Price$11.72

Change0.00%

Shares Out218.10M

Market Cap$2.56B

Enterprise Value$2.38B

52W Range5.37 - 14.26

Beta1.79

P/E-45.54

P/S2.89

P/B1.23

P/FCF-1,182.85

EV/Sales2.70

EV/EBITDA30.96

EV/FCF-1,103.25

Earnings Yield-2.20%

FCF Yield-0.08%

Dividend Yield0.00%

Gross Margin46.93%

Oper. Margin-2.48%

Profit Margin-0.91%

Debt/Eq0.00

Current Ratio3.82

Quick Ratio2.91

Revenue 5Y7.77%

Target$13.50

Target Upside15.19%

Target Median$13.50

Target Range13.00 - 14.00

Volume12.96M

Avg Volume2.74M

EPS Surprise0.05

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

70/100

Potencial de crecimiento

Ingresos y expansión

58/100

Atractivo del precio

Barata o cara hoy

89/100

Por qué este puntaje▼

Flujo de caja libre positivo · 0.68Nivel de deuda manejable · 0Liquidez saludable · 3.82Rentabilidad débil

Analyst view

Analyst sentiment and price target

NEOG

Analyst sentiment

Based on 11 analyst votes · 2026-10-20

68/100

Neutral

Bullish

Hold

Bearish

Precio objetivo

2026-10-08

Bajo

$13.00

Promedio

$13.50

Mediana

$13.50

Alto

$14.00

Resumen de la compañía

IPO: 8/23/1989

Industria: Medical - Devices

P/B i: 1.23

Deuda / Patrimonio i: 0.00

Margen operativo: -2.48%

Margen neto: -0.91%

ROE i: -

ROIC: -

Salud financiera

Puntaje14 / 20

Deuda / Patrimonio: 0.00

Ratio corriente: 3.82

Ratio rápido: 2.91

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

BOREL JAMES C

Transacción: 10/01/2026

COMPRA

Cambio

+20,558

Precio

$12.24

Presentación

10/02/2026

Tipo

COMPRA

BOREL JAMES C

Transacción: 10/01/2026

COMPRA

Cambio

+9,804

Precio

$12.24

Presentación

10/02/2026

Tipo

COMPRA

CAPELLO JEFFREY D

Transacción: 10/01/2026

COMPRA

Cambio

+20,558

Precio

$12.24

Presentación

10/02/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
BOREL JAMES C	COMPRA	+20,558	$12.24	10/01/2026	10/02/2026
BOREL JAMES C	COMPRA	+9,804	$12.24	10/01/2026	10/02/2026
CAPELLO JEFFREY D	COMPRA	+20,558	$12.24	10/01/2026	10/02/2026
CAPELLO JEFFREY D	COMPRA	+9,804	$12.24	10/01/2026	10/02/2026
Green Ronald D	COMPRA	+20,558	$12.24	10/01/2026	10/02/2026
Green Ronald D	COMPRA	+9,804	$12.24	10/01/2026	10/02/2026
Gupta Aashima	COMPRA	+20,558	$12.24	10/01/2026	10/02/2026
Gupta Aashima	COMPRA	+9,804	$12.24	10/01/2026	10/02/2026
Pelossof Avi	COMPRA	+9,804	$12.24	10/01/2026	10/02/2026
Pelossof Avi	COMPRA	+20,558	$12.24	10/01/2026	10/02/2026
RODRIGUEZ RAFAEL A	COMPRA	+20,558	$12.24	10/01/2026	10/02/2026
RODRIGUEZ RAFAEL A	COMPRA	+9,804	$12.24	10/01/2026	10/02/2026
Wainer Andrea F	COMPRA	+9,804	$12.24	10/01/2026	10/02/2026
Wainer Andrea F	COMPRA	+20,558	$12.24	10/01/2026	10/02/2026
Woteki Catherine E	COMPRA	+20,558	$12.24	10/01/2026	10/02/2026
Woteki Catherine E	COMPRA	+9,804	$12.24	10/01/2026	10/02/2026
Nassif Mikheal	VENTA	-20,397	$11.87	08/19/2026	08/20/2026
Moylan John Patrick	VENTA	-2,365	$11.87	08/19/2026	08/20/2026
Nassif Mikheal	COMPRA	+141,631	$11.65	08/14/2026	08/14/2026
Nassif Mikheal	COMPRA	+719,679	$11.65	08/14/2026	08/14/2026

Sobre la compañía

Neogen Corporation

Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary divisions: Food Safety and Animal Safety. The Food Safety segment delivers advanced diagnostic test kits and associated solutions to identify detrimental or unintended contaminants in food and animal feed. This extensive detection capability covers threats such as foodborne pathogens, spoilage-causing organisms, naturally occurring toxins, food allergens, genetically modified ingredients, ruminant by-products, specific meat identification, residual drugs and pesticides, and overall sanitation issues. A key product is the AccuPoint Advanced rapid sanitation test, which quickly spots adenosine triphosphate (ATP), indicating the presence of living cells, to verify cleanliness. Customers for this segment are diverse, encompassing producers and processors of food and feed, grain operations, manufacturers of processed foods like cookies, crackers, candy, and ice cream, as well as those handling meat, poultry, seafood, fruits, vegetables, and dairy. It also serves laboratories and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety division provides a comprehensive portfolio for the animal health market. Offerings include veterinary instruments, pharmaceuticals, vaccines, topical medications, parasiticides, diagnostic products, rodenticides, cleaning agents, disinfectants, insecticides, and genomics testing services. This segment also supplies specialized products for researchers investigating biologically active substances. Its immunoassay test kits are vital for detecting illicit and therapeutic drugs in farm and racing animals, identifying drug residues in meat and meat products, and assisting in human forensic toxicology drug screenings. Moreover, products from this division are instrumental in upholding hygienic conditions and minimizing the risks posed by bacteria, fungi, and viruses. Neogen Corporation was established in 1981 and is headquartered in Lansing, Michigan.

Fuente - Link

Competidores

BCPC ELAN IDXX MRK PAHC ZTS

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOG

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

GlobeNewsWire

NEOG vs. WFCF: Which Food Safety Stock Has Better Prospects?

Neogen beats Where Food Comes From in revenue growth and recovery potential, but higher debt and integration risks complicate the food safety stock showdown.

Zacks Investment Research

Securities Fraud Investigation Into Neogen Corporation (NEOG) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG) investors concerning the Company's possible violations of the federal securities laws.

GlobeNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOG

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation ("Neogen" or the "Company") (NASDAQ: NEOG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

PRNewsWire

Neogen Corporation (NEOG) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-04-09	0.04	0.09	0.05
2026-01-08	0.07	0.1	0.03
2025-10-09	-0.074	0.04	0.114
2025-07-29	0.08	0.05	-0.03
2025-04-09	0.13	0.1	-0.03
2025-01-10	0.09	0.11	0.02
2024-10-10	0.085	0.07	-0.015
2024-07-30	0.12	0.1	-0.02
2024-04-09	0.14	0.12	-0.02
2024-01-09	0.15	0.11	-0.04
2023-10-10	0.14	0.11	-0.03
2023-07-27	0.1	0.14	0.04